The Impact of Ribonucleotide Reductase Enzyme and Zinc on Leukemia
Downloads
Leukemia is a cancer that affects blood cells and their component tissues, such as the bone marrow and lymphatic system. It results from mutations in blood-forming stem cells, leading to abnormal cell growth and proliferation, which hinders normal blood formation. Types of blood cancer (acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL)
Symptoms: anemia, bleeding, recurrent infections, enlarged liver and spleen. Diagnosis: blood tests, bone marrow biopsy, genetic testing, and imaging. Treatment is of two types: chemotherapy (the primary treatment for AML, but its effectiveness decreases in older patients) or stem cell transplantation (used to improve outcomes, especially in younger patients).
Ribonucleotide reductase: Scientific name: Ribonucleotide reductase EC 1.17.4.1 is an essential enzyme and a speed regulator in DNA synthesis, converting ribonucleotides (rNDPs) to deoxyribonucleotides (dNDPs), the building blocks of DNA. It is the enzyme The only known enzyme in cells that converts rNDP to dNDP, and is therefore essential for DNA replication and cell division. Its chemical structure is a complex enzyme consisting of two main protein subunits (RRM1 + RRM2), containing an iron-oxygen center essential for its enzymatic activity. It requires a tyrosine radical to carry out deoxygenation reactions. Its biological effect is the conversion of rNDP to dNDP, which is necessary for DNA synthesis and thus supports cell division, participates in DNA repair, and maintains the balance of nucleotide pools. Any enzyme defect leads to an imbalance in dNTPs → genetic mutations or DNA damage. Its relationship to leukemia: In leukemias (especially AML - Acute Myeloid Leukemia), cancer cells have an excessive need for dNTPs, so: enzyme activity increases significantly; RRM2 levels are particularly high in leukemia cells. The enzyme is considered An important target for cancer therapy.
Zinc is an essential mineral with the chemical symbol Zn and atomic number 30. It is an important trace element in the human body and participates in many biochemical and enzymatic processes. It is found in all cells of the body and is concentrated in muscles, bones, skin, and liver. The body cannot store zinc in large quantities, so it must be obtained regularly from the diet. Patients with acute leukemia may suffer from zinc imbalance due to: Tumor lysis syndrome: zinc is released from dying cancer cells. Chemotherapy also affects the kidneys and electrolyte balance. Kidney dysfunction resulting from the disease. The study aims to understand the relationship between ribulose-5-phosphate isomerase activity and the effect of certain minerals, such as zinc, on the metabolic status of leukemia patients, to understand the biochemical mechanisms that contribute to the progression of the disease and its complications.
1. Guo, S., Wu, X., Lei, T., Zhong, R., Wang, Y., Zhang, L., Zhao, Q., Huang, Y., Shi, Y., & Wu, L. (2022). The role and therapeutic value of syndecan-1 in cancer metastasis and drug resistance. Frontiers in Cell and Developmental Biology, 9, 784983 .
2. Vakiti, A ,.Mewawalla, P., & Wood, S. K. (2023). Acute myeloid leukemia (nursing). In StatPearls [Internet]. StatPearls Publishing .
3. Vardiman, J. W. (2010). The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chemico biological interactions, 184(1-2), 16-20 .
4. Foucar, K. (2023). Diagnostic Pathology: Blood and Bone Marrow-E Book: Elsevier Health Sciences . 3rd Edition:123-130.
5. Han, H. J., Choi, K., & Suh, H. S. (2024). Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: A real-world, population-based longitudinal cohort study. Plos one, 19(5), e0300637 .
6. Radadiya, A., Zhu, W., Coricello, A., Alcaro, S., & Richards, N. G. (2020). Improving the treatment of acute lymphoblastic leukemia. Biochemistry, 59(35), 3193-3200 .
7. Osman, A. E., & Deininger, M. W. (2021). Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood reviews, 49, 100825 .
8. Baliakas, P ,.Jeromin, S., Iskas, M., Puiggros, A., Plevova, K., Nguyen Khac, F., Davis, Z., Rigolin, G. M., Visentin, A., & Xochelli, A. (2020). Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood, The Journal of the American Society of Hematology, 133(11), 1205-1216 .
9. Obeagu, E. I., & Babar, Q. (2021). Acute Myeloid Leukaemia (AML): The Good, the Bad, and the Ugly. Int. J. Curr. Res. Med. Sci, 7(7), 29 41.
10. Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret ,H., Ebert, B. L., Fenaux, P., Godley, L. A., & Hasserjian, R. P. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, The Journal of the American Society of Hematology, 40(12)1345-1377.
11. Heuser, M., Fernandez, C., Hauch, O., Klibanov, O. M., Chaudhary, T., & Rives, V. (2023). Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review. Future Oncology, 19(11), 789-810 .
12. Loke, J., Buka, R., & Craddock, C. (2021). Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how? Frontiers in immunology, 12, 659595 .
13. Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Lazarus, H. M., Rowe, J. M., Paietta, E., Willman, C., Hurd, D. D., Bennett, J. M., & Blume, K. G. (1998). Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New England Journal of Medicine, 339(23), 1649-1656 .
14. Guarino, E., Salguero, I., & Kearsey, S. E. (2014, June). Cellular regulation of ribonucleotide reductase in eukaryotes. In Seminars in cell & developmental biology (Vol. 30, pp. 97-103). Academic Press.
15. Zhou, Z., Song, Q., Yang, Y., Wang, L., & Wu, Z. (2022). Comprehensive landscape of RRM2 with immune infiltration in pan-cancer. Cancers, 14(12), 2938.
16. Kunos, C. A., Chu, E., Beumer, J. H., Sznol, M., & Ivy, S. P. (2017). Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies. Cancer chemotherapy and pharmacology, 79(1), 201-207.
17. Okonska, A., Bühler, S., Rao, V., Ronner, M., Blijlevens, M., van der Meulen-Muileman, I. H., ... & Felley-Bosco, E. (2020). Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated protein 1 induces chemoresistance to ribonucleotide reductase inhibition. Molecular cancer therapeutics, 19(2), 552-563.
18. Prasad, M. N. V. (Ed.). (2013). Heavy metal stress in plants: from biomolecules to ecosystems. Springer Science & Business Media.
19. Ho, Y., Gruhler, A., Heilbut, A., Bader, G. D., Moore, L., Adams, S. L., ... & Tyers, M. (2002). Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature, 415(6868), 180-183.
20. Rink, L. (2000). Zinc and the immune system. Proceedings of the Nutrition Society, 59(4), 541-552.
21. Mocchegiani, E., Costarelli, L., Giacconi, R., Malavolta, M., Basso, A., Piacenza, F., ... & Monti, D. (2014). Vitamin E–gene interactions in aging and inflammatory age-related diseases: Implications for treatment. A systematic review. Ageing research reviews, 14, 81-101.
22. BT-Laboratory. (n.d.). BT Laboratory official website. Retrieved July 24, 2025, from http://www.bt-laboratory.com
23. Kontandreopoulou, C. N., Diamantopoulos, P. T., Giannopoulos, A., Symeonidis, A., Kotsianidis, I., Pappa, V., ... & Hellenic MDS study Group. (2022). Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. Leukemia & Lymphoma, 63(3), 729-737.
24. Cook, G. J., Caudell, D. L., Elford, H. L., & Pardee, T. S. (2014). The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One, 9(11), e112619.
25. Rudd, S. G., Tsesmetzis, N., Sanjiv, K., Paulin, C. B., Sandhow, L., Kutzner, J., ... & Herold, N. (2020). Ribonucleotide reductase inhibitors suppress SAMHD 1 ara‐CTP ase activity enhancing cytarabine efficacy. EMBO molecular medicine, 12(3), e10419.
26. Aimiuwu, J., Wang, H., Chen, P., Xie, Z., Wang, J., Liu, S., ... & Chan, K. K. (2012). RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 119(22), 5229-5238.
27. Wang, W., Lv, Q., Yu, W., Hong, W., Qi, J., Wang, Y., ... & Tang, J. (2024). Cogvlm: Visual expert for pretrained language models. Advances in Neural Information Processing Systems, 37, 121475-121499.
28. Prasad, S., Gupta, S. C., Tyagi, A. K., & Aggarwal, B. B. (2014). Curcumin, a component of golden spice: from bedside to bench and back. Biotechnology advances, 32(6), 1053-1064.
29. Oteíza, T. (2020). Language resources to negotiate official and alternative memories of human rights violations in Chilean history: A study on classroom interactions. Historical Encounters, 7(2), 26-49.
30. Maywald, M., & Rink, L. (2022). Zinc in human health and infectious diseases. Biomolecules, 12(12), 1748.
31. Skrajnowska, D., & Bobrowska-Korczak, B. (2019). Role of zinc in immune system and anti-cancer defense mechanisms. Nutrients, 11(10), 2273.
